Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

100.09
+1.231.24%
Post-market: 100.090.00000.00%19:43 EDT
Volume:342.44K
Turnover:34.21M
Market Cap:1.56B
PE:9.32
High:100.35
Open:98.35
Low:98.35
Close:98.86
52wk High:108.66
52wk Low:72.94
Shares:15.60M
Float Shares:15.60M
Volume Ratio:0.75
T/O Rate:2.20%
Dividend:1.43
Dividend Rate:1.43%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Sector Update: Healthcare

MT Newswires Live
·
15 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
16 hours ago

Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says

MT Newswires Live
·
Yesterday

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Yesterday

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

TIPRANKS
·
Yesterday

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Yesterday

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Veeva Systems (VEEV) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Yesterday

Royalty Pharma to Report Q3 2026 Results, Host Conference Call and Webcast

Reuters
·
Yesterday

Royalty Pharma to Announce Third Quarter 2026 Financial Results on November 4, 2026

THOMSON REUTERS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Yesterday

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Yesterday

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Yesterday

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Yesterday

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Yesterday

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Yesterday
More